Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
Original paper

The activity of pyrazoline B compound in inhibiting proliferation of breast cancer cells with human epidermal growth factor receptor 2 overexpression

Denny Satria
1
,
Syukur Berkat Waruwu
2
,
Eti Nurwening Sholikhah
3
,
Mustofa Mustofa
3
,
Pamungkas Bagus Satriyo
3
,
Tutik Dwi Wahyuningsih
4
,
Hesti L Wiraswati
5
,
Muhammad Hasan Bashari
6
,
Ema Damayanti
7

  1. Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
  2. Pharmacist Professional Education, Faculty of Pharmacy and Health Sciences, Universitas Sari Mutiara Indonesia, Medan, Indonesia
  3. Department of Pharmacology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  4. Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia
  5. Parasitology Division, Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
  6. Pharmacology Division, Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
  7. Research Center for Food Technology and Processing, National Research and Innovation Agency, Gunungkidul, Indonesia
Contemp Oncol (Pozn) 2025; 29 (4): 360–366
DOI: https://doi.org/10.5114/wo.2025.155694
Online publish date: 2025/10/30
Article file
- The activity.pdf  [0.41 MB]
Get citation
 
PlumX metrics:
 
1. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol 2022; 95: 20211033.
2. Yang J, Ju J, Guo L, et al. Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning. Comput Struct Biotechnol J 2022; 20: 333-342.
3. Tapia M, Hernando C, Martínez MT, et al. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel) 2022; 15: 4522.
4. Vernieri C, Milano M, Brambilla M, et al. Resistance mechanisms to anti‑HER2 therapies in HER2‑positive breast cancer: current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 2019; 139: 53-66.
5. Geng W, Thomas H, Chen Z, et al. Mechanisms of acquired resistance to HER2-positive breast cancer therapies induced by HER3: A comprehensive review. Eur J Pharmacol 2024; 977: 176725.
6. Xu L, Han F, Zhu L, et al. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance. Int J Oncol 2023; 62: 48.
7. Liu J, Meng Z, Yidan X. Cardiotoxicity of HER2-targeted drugs when combined with other drugs: a systematic and meta-analysis of randomized controlled trials. Cardiovasc Toxicol 2024; 24: 757-765.
8. Low JL, Wong RSJ, Chan ZY, Lee SC. Health care policies, drug costs, and time toxicities in biologics for HER2‑positive breast cancer: cost minimization analysis of direct and indirect costs. ESMO Real World Data Dig Oncol 2025; 100121.
9. Nassar E. Synthesis, (in vitro) antitumor and antimicrobial activity of some pyrazoline, pyridine, and pyrimidine derivatives linked to indole moiety. J Am Sci 2010; 6: 338-347.
10. Yusuf M, Jain P. Synthetic and biological studies of pyrazolines and related heterocyclic compounds. Arab J Chem 2014; 7: 553-596.
11. Kumari P, Mishra VS, Narayana C, et al. Design and efficient synthesis of pyrazoline and isoxazole bridged indole C-glycoside hybrids as potential anticancer agents. Sci Rep 2020; 10: 6660.
12. Wang H, Zheng J, Xu W, et al. A new series of cytotoxic pyrazoline derivatives as potential anticancer agents that induce cell cycle arrest and apoptosis. Molecules 2017; 22: 1635.
13. Matiadis D, Sagnou M. Pyrazoline hybrids as promising anticancer agents: an up-to-date overview. Int J Mol Sci 2020; 21: 5507.
14. Satria D, Waruwu SB, Sholikhah EN, et al. In silico study of anticancer activity of pyrazoline C and M as potential selective of cyclooxygenase-2 (COX-2) inhibitor using molecular docking and MD simulations. Int J App Pharm 2024; 16: 1-5.
15. Suma AAT, Wahyuningsih TD, Mustofa M. Synthesis, cytotoxicity evaluation and molecular docking study of N-phenylpyrazoline derivatives. Indones J Chem 2019; 19: 1081-1090.
16. Chaudhary M, Kumar N, Baldi A, et al. 4-Bromo-4’-chloro pyrazoline analog of curcumin augmented anticancer activity against human cervical cancer, HeLa cells: in silico -guided analysis, synthesis, and in vitro cytotoxicity. J Biomol Struct Dyn 2020; 38: 1335-1353.
17. Mustofa, Satriyo PB, Suma AAT, et al. A Potent EGFR Inhibitor, N-Phenyl Pyrazoline Derivative Suppresses Aggressiveness and Cancer Stem Cell-Like Phenotype of Cervical Cancer Cells. Drug Des Devel Ther 2022; 16: 23250-2339.
18. Ahmed NM, Youns M, Soltan MK, et al. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma. J Enzyme Inhib Med Chem 2019; 34: 1110-1120.
19. Sever B, Altıntop MD, Tilki EK, et al. Antiproliferative Effects of a Series of Pyrazolines on Lung Cancer. Proceedings 2018; 2: 1574.
20. Satriyo PB, Mustofa M, Wahyuningsih TD, et al. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. Sci Rep 2024; 14: 13200.
21. Wahyuningsih TD, Suma AAT, Astuti E. Synthesis, anticancer activity, and docking study of N-acetyl pyrazolines from veratraldehyde. J Appl Pharm Sci 2019; 9: 14-20.
22. Rana M, Arif R, Khan FI, et al. Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies. Bioorg Chem 2021; 108: 104665.
23. Wiraswati HL, Bashari MH, Alfarafisa NM, et al. Pyrazoline B-Paclitaxel or Doxorubicin Combination Drugs Show Synergistic Activity Against Cancer Cells: In silico Study. Adv Appl Bioinform Chem 2024; 17: 33-46.
24. Wiraswati HL, Bashari MH, Alfarafisa NM, et al. Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors. J Pharm Pharmacogn Res 2023; 11: 699-713.
25. Satria D, Waruwu SB, Sholikhah EN, et al. In-silico analysis of n-phenyl pyrazoline derivates as potential of human epidermal growth receptor-2 (HER-2) inhibitor using molecular docking and MD simulations. Rasayan J Chem 2024; 17: 2.
26. Hasibuan PAZ, Sitorus RKUAB, Hermawan A, et al. Anticancer activity of the ethylacetate fraction of Vernonia amygdalina Delile towards overexpression of HER-2 breast cancer cell lines. Pharmacia 2024; 71: 1-8.
27. Satria D, Hasibuan PAZ, Muhammad M, et al. Cytotoxic and apoptotic effect of Vernonia amygdalina Delile. fractions against Hs578t triple-negative breast cancer cell lines. Phytomedicine Plus 2024; 4: 2667-0313.
28. Chatri M, Hasibuan PAZ, Meiyanto E, et al. Effect of african leaves (Vernonia amygdalina Delile) on the development of T47D breast cancer cells. Trop J Nat Prod Res 2024; 8: 7740-7746.
29. Satria D, Silalahi J, Haro G, et al. Chemical analysis and cytotoxic activity of N-hexane fraction of Zanthoxylum acanthopodium DC. fruits. Rasayan J Chem 2019; 12: 803-808.
30. Inceler N, Yilmaz A, Baytas SN. Synthesis of ester and amide derivatives of 1-phenyl-3-(thiophen-3-yl)-1H- pyrazole-4-carboxylic acid and study of their anticancer activity. Med Chem Res 2013; 22: 3109-3118.
31. Zuo MY, Chen LJ, Jiang H, et al. Detecting endotoxin with a flow cytometry-based magnetic aptasensor. Anal Biochem 2014; 466: 38-43.
32. Ruzinova MB, Benezra R, Id proteins in development, cell cycle and cancer. Trends Cell Biol 2003: 13: 410-418.
33. Chen Q, Kang J, Fu C. The independence of and associations among apoptosis, autophagy, and necrosis. Sig Transduct Target Ther 2018; 3: 18.
34. Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 2023; 22: 138.
35. Atmaca H, Bozkurt E, Cittan M, et al. Effects of Galium aparine extract on the cell viability, cell cycle and cell death in breast cancer cell lines. J Ethnopharmacol 2016; 186: 305-310.
36. Hsin IL, Shen HP, Chang HY, et al. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR Inhibitor PQR309 in endometrial cancer cell lines. Cells. 2021; 10: 2916.
37. Luo L, Sun X, Yang Y, et al. A novel dual PI3K/mTOR inhibitor, XIN-10, for the treatment of cancer. Int J Mol Sci 2023; 24: 14821.
38. Forrester SJ, Kikuchi DS, Hernandes MS, et al. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res 2018; 122: 877-902.
39. Arfin S, Jha NK, Jha SK, et al. Oxidative stress in cancer cell metabolism. Antioxidants 2021; 10: 642.
40. Beckhauser TF, Francis-Oliveira J, De Pasquale R. Reactive oxygen species: Physiological and physiopathological effects on synaptic plasticity. J Exp Neurosci 2016; 23-48.
41. Herb M, Gluschko A, Schramm M. Reactive Oxygen Species: Not Omnipresent but Important in Many Locations. Front Cell Dev Biol 2021; 9: 1-12.
42. Meisel RP, Asgari D, Schlamp F, et al. Induction and inhibition of Drosophila X chromosome gene expression are both impeded by the dosage compensation complex. G3 Genes, Genomes, Genet 2022; 12.
43. Nguyen PL, Lee CH, Lee H, Cho J. Induction of paraptotic cell death in breast cancer cells by a novel Pyrazolo[3,4-h]quinoline derivative through ROS production and endoplasmic reticulum stress. Antioxidants 2022; 11: 117.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.